drugset
drugset / Trial / NCT04829435

Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase)

NCT04829435 ↗

Phase 1 Completed 18 enrolled Allena Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this Phase I study is to evaluate the safety and tolerability of ALLN-346 in in normal healthy volunteers, in an ascending dose design. ALLN-346 is an (oral) enzyme that specifically degrades urate in the intestinal tract.

Timeline

Start
2021-04-21
Primary completion
2021-06-01
Completion
2021-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ALLN-346 Protein / enzyme biologic — Oral

Indications

gout